Preparation, drug release, and cell growth inhibition of a gelatin: Doxorubicin conjugate

Pharmaceutical Research

Volumn 30, Issue 8, 2013, Pages 2087-2096

  Wu, Darren C ^a   Cammarata, Christopher R ^a   Park, Hyun Joo ^a   Rhodes, Brian T ^a   Ofner III, Clyde M ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

acid labile hydrazone; cell growth inhibition; doxorubicin; drug delivery; gelatin; HPLC SEC; macromolecular conjugates

Indexed keywords

DOXORUBICIN; GELATIN;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY; TUMOR CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; GELATIN; HUMANS; MALE; MICE; NEOPLASMS;

EID: 84879799983     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1065-9     Document Type: Article

References (37)

1. Chabner BA, Bertino J, Cleary J, Ortiz T, Lane A, Supko J, et al. Cytotoxic agents. In: Brunton LL, Chabner BA, Knollman BC, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 12 ed. New York: McGraw-Hill; 2011.
2. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-36. Epub 2003/05/13.
3. Minko T, Kopeckova P, Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer. 2000;86(1):108-17. Epub 2000/03/23.
4. Etrych T, Chytil P, Jelinkova M, Rihova B, Ulbrich K. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. effect of spacer on drug release and in vitro cytotoxicity. Macromol Biosci. 2002;2:43-52.
5. Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of curent status and future opportunities. Adv Drug Deliv Rev. 2010;62:272-82.
6. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91(10):1775-81. Epub 2004/10/13.
7. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, et al. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release Off J Control Release Soc. 2000;64(1-3):143-53. Epub 2000/01/21.
8. Lu D, Wen X, Liang J, Gu Z, Zhang X, Fan Y. A pH-sensitive nano drug delivery system derived from pullulan/doxorubicin conjugate. J Biomed Mater Res Part B: Appl Biomater. 2009;89(1):177-83. Epub 5 September 2008.
9. Ghoroghchian PP, Li G, Levine DH, Davis KP, Bates FS, Hammer DA, et al. Bioresorbable vesicles formed through spontaneous self-assembly of amphiphilic poly(ethylene oxide)-block-polycaprolactone. Macromolecules. 2006;39(5):1673-5. Epub 2006/03/07.
10. Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials. 2010;31(10):2882-92. Epub 2010/01/08.
11. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release Off J Control Release Soc. 2000;65(1-2):271-84. Epub 2000/03/04.
12. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-60. Epub 2003/05/17.
13. Etrych T, Chytil P, Mrkvan T, Sirova M, Rihova B, Ulbrich K. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. J Control Release Off J Control Release Soc. 2008;132(3):184-92. Epub 2008/06/07.
14. Ayen WY, Kumar N. In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox. Pharm Res. 2012;29(9):2522-33. Epub 2012/06/07.
15. Sirova M, Mrkvan T, Etrych T, Chytil P, Rossmann P, Ibrahimova M, et al. Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model. Pharm Res. 2010;27(1):200-8. Epub 2009/11/07.
16. Minko T, Kopeckova P, Kopecek J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release Off J Control Release Soc. 1999;59(2):133-48. Epub 1999/05/20.
17. Nan A, Ghandehari H, Hebert C, Siavash H, Nikitakis N, Reynolds M, et al. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. J Drug Target. 2005;13(3):189-97. Epub 2005/07/23.
18. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5(1):83-94. Epub 1999/01/26.
19. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(10):3185-91. Epub 1997/10/23.
20. Wang X, Zhao G, Van S, Jiang N, Yu L, Vera D, et al. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol. 2010;65(3):515-26. Epub 2009/07/14.
21. Veis A. The macromolecular chemistry of gelatin. New York: Academic; 1964.
22. Nahar M, Dubey V, Mishra D, Mishra PK, Dube A, Jain NK. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target. 2010;18(2):93-105. Epub 2009/07/31.
23. Bowman BJ, Ofner 3rd CM. Characterization and In vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity. Pharm Res. 2000;17(10):1309-15.
24. Tabata Y, Uno K, Ikada Y, Muramatsu S. Suppressive effect of recombinant TNF-gelatin conjugate on murine tumour growth in-vivo. J Pharm Pharmacol. 1993;45(4):303-8. Epub 1993/04/01.
25. Ofner 3rd CM, Pica K, Bowman BJ, Chen CS. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates. Int J Pharm. 2006;308(1-2):90-9. Epub 2005/12/20.
26. Etrych T, Kovar L, Strohalm J, Chytil P, Rihova B, Ulbrich K. Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-tumor efficacy. J Control Release Off J Control Release Soc. 2011;154(3):241-8. Epub 2011/06/28.
27. Etrych T, Subr V, Strohalm J, Sirova M, Rihova B, Ulbrich K. HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity. J Control Release Off J Control Release Soc. 2012;164(3):346-54. Epub 2012/07/05.
28. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev. 2004;56(7):1023-50. Epub 2004/04/07.
29. Bubnis WA, Ofner 3rd CM. The determination of epsilon-amino groups in soluble and poorly soluble proteinaceous materials by a spectrophotometric method using trinitrobenzenesulfonic acid. Anal Biochem. 1992;207(1):129-33. Epub 1992/11/15.
30. King TP, Zhao SW, Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry. 1986;25(19):5774-9. Epub 1986/09/23.
31. Cammarata CR, Wu DC, Ofner CM, 3rd. Developing a spectrophotometric assay for hydrazide group determination as an evaluation of a gelatin conjugate precursor. Poster presentation at the 2011 AAPS Annual Meeting and Exposition; October 23-27, 2011; Washington, D.C. Poster R6004.
32. Dupont AL. Study of the degradation of gelatin in paper upon aging using aqueous size-exclusion chromatography. J Chromatogr A. 2002;950(1-2):113-24. Epub 2002/05/07.
33. Wu DC, Ofner CM, 3rd. Adsorption and degradation of doxorubicin from aqueous solution in polypropylene containers. AAPS PharmSciTech. 2012. Epub 2012/12/12.
34. van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, et al. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol. 2002;63(5):897-908. Epub 2002/03/26.
35. Tanner GA, Rippe C, Shao Y, Evan AP, Williams Jr JC. Glomerular permeability to macromolecules in the Necturus kidney. Am J Physiol Renal Physiol. 2009;296(6):F1269-78. Epub 2009/04/03.
36. Kunath K, Kopeckova P, Minko T, Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2000;49(1):11-5. Epub 1999/12/30.
37. Ulbrich K, Etrych T, Chytil P, Jelinkova M, Rihova B. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J Control Release Off J Control Release Soc. 2003;87(1-3):33-47. Epub 2003/03/06.